Prelude Therapeutics Inc (NASDAQ: PRLD) on Monday, soared 20.00% from the previous trading day, before settling in for the closing price of $2.45. Within the past 52 weeks, PRLD’s price has moved between $0.61 and $4.22.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -21.61%. The company achieved an average annual earnings per share of 20.44%. With a float of $27.77 million, this company’s outstanding shares have now reached $43.75 million.
Prelude Therapeutics Inc (PRLD) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prelude Therapeutics Inc is 50.95%, while institutional ownership is 28.76%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.37 earnings per share (EPS) for the period topping the consensus outlook (set at -0.47) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.44% per share during the next fiscal year.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Prelude Therapeutics Inc (PRLD) is currently performing well based on its current performance indicators. A quick ratio of 3.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Compared to the last year’s volume of 0.51 million, its volume of 0.56 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 90.62%.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 63.11%, which indicates a significant decrease from 96.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.23 in the past 14 days, which was higher than the 0.20 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.71, while its 200-day Moving Average is $1.14. Nevertheless, the first resistance level for the watch stands at $3.17 in the near term. At $3.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.81. If the price goes on to break the first support level at $2.53, it is likely to go to the next support level at $2.13. Should the price break the second support level, the third support level stands at $1.89.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
Market capitalization of the company is 166.45 million based on 62,865K outstanding shares. Right now, sales total 7,000 K and income totals -127,170 K. The company made 6,500 K in profit during its latest quarter, and -19,730 K in sales during its previous quarter.
